• Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker-Herceg, R., Hilberg, F., ... & Kaiser, R. (2015). Nintedanib: from discovery to the clinic. Journal of medicinal chemistry, 58(3), 1053-1063.
• Richeldi, L., Du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., ... & Collard, H. R. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2071-2082.
• Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 45(5), 1434-1445.
• Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., ... & Thannickal, V. J. (2016). Novel mechanisms for the antifibrotic action of nintedanib. American journal of respiratory cell and molecular biology, 54(1), 51-59.
• Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., ... & Dallinger, C. (2019). Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clinical pharmacokinetics, 58(9), 1131-1147.